Regulatory Issues

Health Of Drug Industry Depends On Reducing Patent Litigation

Published in Medical Letter on the CDC and FDA, June 24th, 2001

"We need to find a way to better use the energy and funds now being directed at gimmicks and litigation," says Gerald F. Meyer, former U.S. Food and Drug Administration (FDA) deputy director of the Center for Drug Evaluation and Research, about the process for allowing innovative drugs to be produced as generics.

He sees misdirected energy and dollars spent on litigation or circumventing intellectual property rights protections as "exceptional and unfortunate - and generally destructive in terms of drug development in [the U.S.]" He calls instead for members of industry, the Food and Drug Bar, and congressional committees to work together to carve out a fair approach...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2001-06-24)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry